Nitric oxide inhalation - Vero Biotech
Alternative Names: GeNOsyl; GENOSYL (nitric oxide) gas; GENOSYL Delivery System; GENOSYL® inhaled nitric oxide ; GENOSYL®DS; inhaled Nitric oxide - VERO Biotech; iNO - VERO Biotech; MVG-2000Latest Information Update: 04 Dec 2025
At a glance
- Originator GeNO LLC
- Developer Vero Biotech
- Class Anti-infectives; Anti-inflammatories; Antiacnes; Antiandrogens; Antibacterials; Antibronchitics; Antifibrotics; Antifungals; Antihypertensives; Antineoplastics; Antituberculars; Antivirals; Cardiovascular therapies; Diagnostic agents; Foot disorder therapies; Free radicals; Nitrogen oxides; Non-opioid analgesics; Skin disorder therapies; Small molecules; Vascular disorder therapies; Vasodilators
- Mechanism of Action Androgen receptor antagonists; Angiogenesis inducing agents; Cell death stimulants; Guanylate cyclase stimulants; Nitric oxide donors; Reactive oxygen species modulators
-
Orphan Drug Status
Yes - Hypoxic respiratory failure
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Anaesthesia; Hypoxic respiratory failure
- Phase II Pulmonary arterial hypertension
- No development reported Cardiovascular disorders